GVBL

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Genomic Valley latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

Balance sheet of Genomic Valley is strong. It shouldn't have solvency or liquidity issues.

The profit is oscillating. The profit of Genomic Valley is ₹0.02 Crs for Mar 2024, ₹0.65 Crs for Mar 2023 and -₹0.01 Crs for Mar 2022

Yes, The net debt of Genomic Valley is increasing. Latest net debt of Genomic Valley is -₹0.01 Crs as of Sep-25. This is greater than Mar-24 when it was -₹0.01 Crs.

Genomic Valley is not expensive. Latest PE of Genomic Valley is 93.6, while 3 year average PE is 99.03. Also latest EV/EBITDA of Genomic Valley is 47.57 while 3yr average is 87.84.

Genomic Valley has given better returns compared to its competitors. Genomic Valley has grown at ~11.83% over the last 2yrs while peers have grown at a median rate of 5.38%

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Genomic Valley is 46.72% and last quarter promoter holding is 46.72%.

There is Insufficient data to gauge this.